



## ASX and Media Release

# CAVATAK™ ASCO Poster & CALM Trial Recruitment Milestone Achieved

---

**4 June 2013, Sydney, Australia:** Viralytics Limited (ASX:VLA, OTC:VRACY) is pleased to announce:

- Poster on CALM trial presented today at ASCO; and
- Stage 1 recruitment milestone of 35 patients achieved.

### **CALM Trial ASCO poster**

Dr Robert Andtbacka, the lead study investigator, based at the Huntsman Cancer Institute, Utah, has today presented a poster outlining the design and progress of the phase 2 clinical trial of **CAVATAK™** in Late stage **Melanoma** patients (CALM) at the annual meeting of the American Society of Clinical Oncology (ASCO).

The poster, available on the Viralytics website, is entitled:

*"CALM study: A phase II study of intratumoral Coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma"*

ASCO is the world's most prestigious oncology conference with over 31,000 attendees from the global oncology community.

Dr Andtbacka reported that 35 patients have been enrolled with a target of 54 evaluable patients. Patients injected have not experienced any treatment related serious adverse events. As previously reported, the interim efficacy milestone of at least three objective responses has already been achieved.

Dr Andtbacka said, *"Based on my experience I am encouraged by the early results with CAVATAK™. The drug has been well tolerated with activity in both injected and metastatic lesions."*

### **CALM Stage 1 recruitment completed**

The enrolment of the 35<sup>th</sup> patient completes the Stage 1 patient recruitment in the CALM clinical trial. As per the study protocol the independent data monitoring committee (DMC) will convene in the third quarter of 2013 to review the Stage 1 interim efficacy and patient tolerability to multiple CAVATAK™ injections.

For personal use only



*"Completing Stage 1 enrolment is a significant milestone and we are very pleased with the accelerated recruitment rate through 2013. With nine current clinical trial sites and additional sites planned to enter the study we look forward to strong progress in the second half of 2013,"* said Dr Malcolm McColl, Viralytics' Chief Executive Officer.

**Enquiries:  
Dr Malcolm McColl  
02 9988 4000**

**Rudi Michelson  
Monsoon Communications  
03 9620 3333**

---

**About Viralytics Ltd:**

Viralytics is developing oncolytic virotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells, by direct cytolysis and a possible immune response. The preferential targeting of cancer rather than healthy cells provides the potential for low toxicity in the patient. The company is actively enrolling a phase II clinical trial, of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. Viralytics plans to commence a Phase I/II trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. Subject to regulatory approval the STORM trial will commence at three prominent UK sites later in 2013.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTC market.

For personal use only